Advertisement
News
Advertisement

Dyax licenses oncology technology to Eclipse

Tue, 04/17/2012 - 8:33am
Mass High Tech: The Journal of New England Technology

Dyax Corp. (Nasdaq: DYAX), which recently moved to Burlington from Cambridge, said it has granted Eclipse Therapeutics Inc. of San Diego an exclusive worldwide license to develop and commercialize preclinical fully-human antibodies using Dyax’s phage display technology for oncology indications.

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading